HomeNewsBusinessCOVID-19 didn’t hit Railways business hard, more orders expected: Texmaco Rail deputy MD Ashish Gupta

COVID-19 didn’t hit Railways business hard, more orders expected: Texmaco Rail deputy MD Ashish Gupta

There will be a lot more opportunities to produce rolling stock, both coaches and locomotives, with the entry of private players in the market, Gupta says.

September 21, 2021 / 17:54 IST
Story continues below Advertisement
Ashish Gupta.
Ashish Gupta.

India’s market for rolling stock, or railway wagons, coaches and locomotives, has completely recovered from the impact of COVID-19, and the sector is now looking at even more orders from the massive expansion planned by the network, Ashish Gupta, Deputy Managing Director, Texmaco Rail & Engineering told Moneycontrol in an interview.

He said procurement by the Indian railways remained strong despite the pandemic, and the company is eyeing opportunities in bidding for tenders in setting up of The National High Speed Railways, metros, and the dedicated freight corridors.

Story continues below Advertisement

He also said an independent regulator was need for public-private partnership to work in the railways, and entry of the private players in train operations will significantly expand the market.

Edited Excerpts:

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show